Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures, infantile spasm, mixed seizure types of Lennox–Gastaut syndrome, myoclonic, and generalized tonic clonic seizure.
CAT No: 10-101-130
CAS No:68291-97-4
Synonyms/Alias:AD-810; CI-912; PD-110843; 1,2-Benzisoxazole-3-methanesulfonamide; 3-(Sulfamoylmethyl)-1,2-benzisoxazole; Benzo[d]isoxazol-3-yl-methanesulfonamide
Zonisamide is a synthetic sulfonamide derivative with a unique bicyclic structure, primarily recognized for its activity as a modulator of neuronal excitability. As a small molecule with both hydrophilic and lipophilic properties, Zonisamide exhibits excellent membrane permeability, making it a valuable tool in neurochemical research and pharmaceutical development. Its molecular framework is composed of a benzisoxazole ring fused to a sulfonamide group, conferring it with the ability to interact with various biological targets, particularly voltage-gated ion channels and enzymes involved in neuronal signaling pathways. The compound's versatility and stability under a range of laboratory conditions have contributed to its widespread adoption in the study of central nervous system (CNS) function, as well as in the exploration of neuroprotective strategies and metabolic modulation.
Neuroscience Research: Zonisamide is extensively utilized in neuroscience research to investigate the mechanisms underlying neuronal excitability and synaptic transmission. By modulating voltage-gated sodium and calcium channels, the compound serves as a key probe for dissecting ion channel function in cultured neurons or brain slice preparations. Researchers employ it to study the effects of channel inhibition on action potential propagation, network synchronization, and neurotransmitter release, providing critical insights into the molecular basis of CNS disorders and the development of novel therapeutic approaches.
Neuroprotection Studies: In the context of neuroprotection, Zonisamide is frequently applied in experimental models to examine its ability to mitigate cellular damage caused by oxidative stress or excitotoxic insults. Its antioxidant properties, coupled with its capacity to modulate glutamatergic signaling, enable researchers to evaluate neuroprotective mechanisms in vitro and in vivo. Studies often focus on the compound's impact on mitochondrial function, reactive oxygen species production, and apoptotic pathways, offering valuable data for the identification of potential targets for neurodegenerative disease intervention.
Metabolic Modulation: The sulfonamide derivative is also investigated for its effects on cellular metabolism, particularly in neuronal and glial cells. Zonisamide's influence on carbonic anhydrase activity and mitochondrial bioenergetics is of particular interest in studies aimed at understanding metabolic adaptation in the CNS. Researchers utilize it to probe the interplay between ion homeostasis, energy metabolism, and cellular survival, facilitating the exploration of metabolic vulnerabilities in various neurological conditions.
Drug Discovery and Screening: Zonisamide serves as a reference compound in drug discovery pipelines focused on ion channel modulators and neuroactive agents. Its well-characterized pharmacological profile allows for its use as a benchmark in high-throughput screening assays, enabling the identification and optimization of novel compounds with similar or improved activity. The compound's diverse range of molecular interactions provides a foundation for structure-activity relationship (SAR) studies and the rational design of new chemical entities targeting CNS pathways.
Pharmacokinetic and Transport Studies: In pharmacokinetic research, Zonisamide is employed to elucidate the mechanisms governing blood-brain barrier permeability and drug distribution within the CNS. Its dual solubility characteristics make it an ideal candidate for studying passive and active transport processes in cellular and animal models. Researchers analyze its absorption, distribution, and elimination profiles to inform the development of CNS-targeted delivery systems and to optimize drug formulations for enhanced brain penetration.
Chemical Biology and Mechanistic Investigations: Beyond its direct neurological applications, Zonisamide is leveraged in chemical biology to unravel the molecular mechanisms underlying its diverse biological effects. Its interactions with enzymes, transporters, and signaling molecules are explored using a variety of analytical and imaging techniques, contributing to a deeper understanding of sulfonamide pharmacology and the broader landscape of CNS-active small molecules. The compound's robust performance in multiple experimental contexts underscores its continued relevance as a research tool in the fields of neurobiology, pharmacology, and chemical biology.
Zonisamide is a modern antiepileptic drug (AED) that is distinguished from other AEDs by its unique structure and broad mechanistic profile. Preclinical studies have reported a range of potential mechanisms of action for zonisamide, such as blocking voltage-gated sodium channels, reduction of T-type calcium channel currents, and enhancement of gamma-aminobutyric acid (GABA)-mediated inhibition, which are indicative of its broad antiseizure effects. Zonisamide has a favorable linear pharmacokinetic profile, a long half-life, and a low incidence of protein-binding interactions with other AEDs.
Wilfong, A. A., & Willmore, L. J. (2006). Zonisamide–a review of experience and use in partial seizures. Neuropsychiatric disease and treatment, 2(3), 269.
The limitations of currently available therapies in addressing the non motor symptoms of Parkinson's disease (PD) have egged on the search for newer options. Zonisamide has been in use for epilepsy and it was serendipitously found to improve the symptoms of PD in a patient who had both epilepsy and PD. Thereafter, various trials were designed to assess the use of zonisamide in PD. The present article investigates the evidence for use of zonisamide in PD from the various clinical trials that were designed to address this issue. Furthermore, the article also summarizes the various mechanisms of its use in PD as described in various animal experiments.
Grover, N. D., Limaye, R. P., Gokhale, D. V., & Patil, T. R. (2013). Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease. Indian journal of pharmacology, 45(6), 547.
Epilepsy is one of the most common neurologic disorders, affecting about 50 million people around the world. It is recognized that around 50% of patients with newly diagnosed epilepsy become seizure-free with the first drug treatment, so the choice of first antiepileptic drug is crucial. This paper provides a comprehensive overview of zonisamide as monotherapy for partial seizures, with special attention to the possibility of a once-daily regimen. The available data suggest that zonisamide is an effective and well tolerated option as monotherapy.
Mula, M. (2013). Profile of once-daily zonisamide as monotherapy for treatment of partial seizures in adults. Drug design, development and therapy, 7, 397.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More